Return to study ST002732 main page
MB Sample ID: SA274829
| Local Sample ID: | P_100 |
| Subject ID: | SU002838 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO002831 |
| Collection Summary: | Patients included in this study (211 female subjects with median age of 43.5 years [range 19-78 years]) were followed at the French National Reference Center for SLE (Pitié-Salpêtrière Hospital, Paris, France) between January 2014 and December 2017. SLE was defined according to international guidelines (ACR) 19. Antiphospholipid syndrome (APS) was defined according to the revised Sapporo criteria 20. Each patient underwent a multi-detector CT scan (Siemens syngo.CT CaScoring) and CAC was quantified by means of the previously described Agatston scoring method 21. Duration of the disease, clinical involvements (skin, seritis, hematology, joints and nervous system), treatment regimens (steroids, methotrexate and hydroxychloroquine) and SLE variables (C3, anti-dsDNA, anti-nuclear and antiphospholipid (aPL) antibodies) are presented in Table 1. Disease activity was estimated by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. The presence of cardiovascular risk factors, including hypertension, hypercholesterolemia, diabetes, obesity, smoking status, family or previous personal history of cardiovascular events and inflammation (US-CRP) was determined for all patients (Table 1). Patients were classified into 3 groups of coronary heart disease (CHD) risk according to the calcium score as defined by the Multi-Ethnic Study of Atherosclerosis (MESA) study 22 (low, CAC=0; moderate, 0 < CAC < 100, and high, CAC > 100). |
| Sample Type: | Blood (plasma) |
